Core Insights - American Oncology Network (AON) showcased multiple research studies at the ASCO 2025 Annual Meeting, highlighting its commitment to advancing cancer care through evidence-based practices [1][6][8] - AON's participation reflects the organization's focus on innovation, collaboration, and improving patient outcomes in oncology [6][8] Research Highlights - AON physicians co-authored studies on various topics, including the safety and efficacy of ABBV-706 in neuroendocrine neoplasms, racial representation in clinical trials, and real-world outcomes of HER2 directed therapy in early-stage breast cancer [4][5] - Specific studies presented include: - "Bria-IMT + checkpoint inhibitor" in metastatic breast cancer [4] - "Impact of HLA matching on clinical outcomes" in advanced breast cancer [4] - "Real-world data on bispecific antibodies administration" in community oncology settings [5] - AON practices currently offer access to over 150 clinical trials, providing cutting-edge treatment options within local communities [7] Organizational Overview - AON is an alliance of over 290 providers across 21 states, founded in 2018, focusing on community oncology and innovative healthcare solutions [8] - The organization emphasizes value-based care, aiming to improve patient outcomes while reducing costs and expanding access to quality care [8] - AON is committed to promoting health equity and addressing disparities in cancer care [8]
American Oncology Network Announces Research Studies Presented at ASCO 2025 Annual Meeting